CTOs on the Move

The Portland Clinic

www.theportlandclinic.com

 
At The Portland Clinic, we’ve been treating the people in our community with trust, kindness and understanding for nearly 100 years. For us, that means asking good questions and paying close attention to your answers. Working hard to find out where you...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Valeant Canada Limited

Valeant Canada Limited is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apex Clinical

Apex Clinical is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sutro Biopharma

At Sutro Biopharma, a clinical stage company, we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Encore Dermatology

Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).